BMRN Overview

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is87.35 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioMarin Pharmaceutical Inc revenue for the last quarter amounts to 874.57M USD, increased 17.03

BioMarin Pharmaceutical Inc. EPS for the last quarter amounts to -0.24 USD, decreased -137.50

BioMarin Pharmaceutical Inc (BMRN) has 3221 emplpoyees as of March 12 2026.

Today BMRN has the market capitalization of 11.60B USD.